1	European Autism GEnomics Registry (EAGER):
2	Protocol for a multicentre cohort study and registry
3	
4	Authors:
5	Bloomfield, M. <sup>1</sup> *, Lautarescu, A. <sup>1</sup> *, Heraty, S. <sup>2</sup> , Douglas, S. <sup>3</sup> , Violland, P. <sup>3</sup> , Plas, R. <sup>3</sup> , Ghosh,
6	A. <sup>3</sup> , Van den Bosch, K. <sup>3</sup> , Eaton, E. <sup>4</sup> , Absoud, M. <sup>5,6</sup> , Battini, R. <sup>7,8</sup> , Blázquez Hinojosa, A. <sup>9</sup> ,
7	Bolshakova, N. <sup>10</sup> , Bolte, S. <sup>11,12,13</sup> , Bonanni, P. <sup>14</sup> , Borg, J. <sup>15,16</sup> , Calderoni, S. <sup>7,8</sup> , Calvo
8	Escalona, R. <sup>9,17,18,19</sup> , Castelo-Branco, M. <sup>20</sup> , Castro-Fornieles, J. <sup>9,17,18,19</sup> , Caro P. <sup>21</sup> , Danieli,
9	A. <sup>14</sup> , Delorme, R. <sup>22</sup> , Elia, M. <sup>23</sup> , Hempel, M. <sup>21</sup> , Madeira, N. <sup>24,25,26</sup> , McAlonan, G. <sup>27,28</sup> , Milone,
10	R. <sup>7</sup> , Molloy, C. J. <sup>10</sup> , Mouga, S. <sup>29,30</sup> , Montiel, V. <sup>31</sup> , Pina Rodrigues, A. <sup>29,30</sup> , Schaaf, C. P. <sup>21</sup> ,
11	Serrano, M. <sup>31</sup> , Tammimies, K. <sup>11,32</sup> , Tye, C. <sup>1</sup> , Vigevano, F. <sup>33</sup> , Oliveira, G. <sup>34,35</sup> , Mazzone, B. <sup>7</sup> ,
12	O'Neill, C. <sup>36</sup> , Romero, V. <sup>37</sup> , Tillmann, J. <sup>38</sup> , Oakley, B. <sup>27</sup> , Murphy, D. <sup>27,39,40</sup> , Gallagher,
13	L. <sup>10,41,42,43</sup> , Bourgeron, T. <sup>44</sup> , Chatham, C. <sup>45</sup> , Charman, T. <sup>1</sup>
14	* Indicates equal contribution
15	
16	Affiliations:
17	1 - Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's
18	College London, London, United Kingdom
19	2 - Department of Psychological Sciences, University of London, Birkbeck, London, United
20	Kingdom
21	3 - AIMS-2-Trials A-Reps, University of Cambridge, Cambridge, United Kingdom

22 4 - Autism Research Centre, University of Cambridge, Cambridge, United Kingdom

- 23 5 Department of Children's Neurosciences, Evelina London Children's Hospital, Guy's and
- 24 St Thomas' NHS Foundation Trust, London, United Kingdom
- 25 6 Department of Women and Children's Health, Faculty of Life Sciences and Medicine,
- 26 School of Life Course Sciences, King's College London, London, United Kingdom
- 27 7 Department of Developmental Neuroscience, IRCCS, Fondazione Stella Maris, Pisa, Italy
- 28 8 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 29 9 Department of Child and Adolescent Psychiatry and Psychology, Institute of
- 30 Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- 31 10 Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
- 32 11 Center of Neurodevelopmental Disorders (KIND), Department of Women's and
- 33 Children's Health, Centre for Psychiatry Research, Karolinska Institutet & Region Stockholm,
- 34 Stockholm, Sweden
- 35 12 Child and Adolescent Psychiatry, Stockholm Health Care Services, Region Stockholm,
- 36 Stockholm, Sweden
- 13 Curtin Autism Research Group, Curtin School of Allied Health, Curtin University, Perth,
   Australia
- 39 14 Epilepsy Unit, Scientific Institute IRCCS E. Medea Conegliano, Treviso, Italy
- 40 15 Centre for Psychiatry Research and Centre for Cognitive and Computational
- 41 Neuropsychiatry (CCNP), Department of Clinical Neuroscience, Karolinska Institutet &
- 42 Stockholm Health Care Services, Region Stockholm, Sweden
- 43 16 Psykiatri Affektiva, Sahlgrenska University Hospital, Gothenburg, Sweden
- 17 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- 45 18 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain

- 46 19 Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona,
- 47 Spain
- 48 20 CIBIT, ICNAS, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 49 21 Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
- 50 22 Child and Adolescent Psychiatry Department, Robert Debre Hospital, APHP, Université
- 51 Paris Cité, Paris, France
- 52 23 Unit of Neurology and Clinical Neurophysiopathology, Oasi Research Institute-IRCCS,
- 53 Troina, Italy
- 54 24 Psychiatry Department, Centro Hospitalar e Universitário de Coimbra, Coimbra,
- 55 Portugal
- 56 25 Coimbra Institute for Biomedical Imaging and Translational Research, University of
- 57 Coimbra, Coimbra, Portugal
- 58 26 Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra,
- 59 Coimbra, Portugal
- 60 27 Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry,
- 61 Psychology & Neuroscience, King's College London, London, United Kingdom
- 62 28 Behavioural and Developmental Clinical Academic Group, South London and Maudsley
- 63 NHS Foundation Trust, London, United Kingdom
- 64 29 CIBIT Coimbra Institute for Biomedical Imaging and Translational Research, University
- 65 of Coimbra, Coimbra, Portugal
- 30 ICNAS Institute of Nuclear Sciences Applied to Health, University of Coimbra,
- 67 Coimbra, Portugal
- 68 31 Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant
- 69 Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

- 70 32 Astrid Lindgren Children's Hospital, Karolinska University Hospital, Region Stockholm,
- 71 Stockholm, Sweden
- 72 33 Neurological Sciences and Rehabilitation Medicine Scientific Area Bambino Gesù
- 73 Children's Hospital, Rome, Italy
- 74 34 University Clinic of Pediatrics, Faculty of Medicine, University of Coimbra, 3000-602
- 75 Coimbra, Portugal
- 76 35 Child Developmental Center and Research and Clinical Training Center, Pediatric
- Hospital, Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-602 Coimbra, Portugal
- 78 36 Cure Sanfilippo Foundation
- 79 37 Dup15q Alliance
- 38 Roche Pharma Research and Early Development, Roche Innovation Center Basel,
- 81 Basel, Switzerland
- 39 South London and Maudsley NHS Foundation Trust (SLaM), London SE5 8AZ, UK
- 40 Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology &
- 84 Neuroscience, King's College London, London WC2R 2LS, UK
- 41 Department of Psychiatry at The Hospital for Sick Children
- 86 42 Child and Youth Division Centre for Addiction and Mental Health, CAMH
- 43 Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto
- 44 Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS,
- 89 Université de Paris Cité, IUF, Paris, France
- 90 45 F. Hoffman-La Roche Ltd, Basel, Switzerland
- 91

# 93 Corresponding author

94	Dr Alexandra Lautarescu, Department of Psychology, Institute of Psychiatry, Psychology &
95	Neuroscience, King's College London, Alexandra.Lautarescu@kcl.ac.uk
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	

# 114 ABSTRACT

115	Introduction: Autism is a common neurodevelopmental condition with a complex genetic
116	aetiology that includes contributions from monogenic and polygenic factors. Many autistic
117	people have unmet healthcare needs that could be served by genomics-informed research
118	and clinical trials. The primary aim of the European Autism GEnomics Registry (EAGER) is
119	to establish a registry of participants with a diagnosis of autism or an associated rare genetic
120	condition who have undergone whole-genome sequencing. The registry can facilitate
121	recruitment for future clinical trials and research studies, based on genetic, clinical, and
122	phenotypic profiles, as well as participant preferences. The secondary aim of EAGER is to
123	investigate the association between mental and physical health characteristics and
124	participants' genetic profiles.
125	Methods and analysis: EAGER is a European multisite cohort study and registry and is part
126	of the AIMS-2-TRIALS consortium. EAGER was developed with input from the AIMS-2-
127	TRIALS Autism Representatives and representatives from the rare genetic conditions
128	community. 1,500 participants with a diagnosis of autism or an associated rare genetic
129	condition will be recruited at 13 sites across 8 countries. Participants will give a blood or
130	saliva sample for whole-genome sequencing and answer a series of online questionnaires.
131	Participants may also consent for the study to access pre-existing clinical data. Participants
132	will be added to the EAGER registry. Data will be shared via the Autism Sharing Initiative, a
133	new international collaboration aiming to create a federated system for autism data sharing.
134	Ethics and dissemination: EAGER has received full ethical approval from ethics
135	committees in the UK (REC 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023)
136	and Spain (HCB/2023/0038, PIC-164-22). Approvals are in the process of being obtained
137	from committees in Italy, Sweden, Ireland, and France. Findings will be disseminated via
138	scientific publications and conferences, but also beyond to participants and the wider
139	community (e.g., the AIMS-2-TRIALS website, stakeholder meetings, newsletters).

#### 140

162

# 141 STRENGHTS AND LIMITATIONS OF THIS STUDY

142 Data from full genotyping through whole-genome sequencing will be combined with • 143 mental and physical health data and participant research priorities The EAGER sample (n=1,500), although relatively small for genetic analyses, will include 144 • 145 a substantial proportion (around one third) of participants with a rare genetic condition, 146 ensuring that heterogeneous presentations across the autism spectrum are captured 147 The EAGER registry will improve the speed, efficiency, and impact of research studies • 148 and clinical trials across Europe with a culturally diverse cohort of re-contactable 149 participants, and shared data through the Autism Sharing Initiative 150 EAGER was developed with input from the AIMS-2-TRIALS Autism Representatives and • 151 representatives from the rare genetic conditions community 152 Phenotypic data are collected only via self/informant-report questionnaires and not direct • 153 clinical assessments 154 155 156 157 158 159 160 161

#### 163 **1. INTRODUCTION**

164

165	Autism is a neurodevelopmental condition diagnosed on the basis of differences in social
166	communication and interaction, sensory processing, restricted and repetitive behaviours,
167	and intense interests (1,2), with a prevalence of around 1-2% of the general population (3).
168	Autism is associated with a very large number of common genetic variants of small effect
169	(4), as well as being associated with several rare genetic conditions such as Dup15q
170	syndrome, Rett syndrome, tuberous sclerosis complex, and Angelman syndrome, where
171	autism prevalence is as high as 30-93% (5,6).

172

173 Many autistic people have co-occurring mental and physical health conditions that impact 174 quality of life, such as depression, anxiety, gastrointestinal symptoms, and epilepsy (7-12). 175 For some autistic people and those with associated rare genetic conditions, many of these 176 conditions can be severe and life-limiting, including respiratory and cardiac disorders in Rett 177 syndrome (13,14), hyperphagia in Prader-Willi syndrome (15), and tumour growth in 178 tuberous sclerosis complex (16). This makes the development of treatments and support for 179 these populations a crucial area of research. Further, some autistic people may find aspects 180 of being autistic distressing and disabling and may want help with these (17–20). All autistic 181 people have the right to evidence-based care and support for aspects that are detrimental to 182 their quality of life and wellbeing (21). Despite this, there is currently a paucity of 183 personalised evidence-based care and support for autistic people across the spectrum 184 (22,23), and polypharmacy (i.e., taking multiple medications) for various co-occurring 185 symptoms is commonplace (24).

186

187 With a heritability of around 80%, autism has strong genetic influences (e.g., 25,26). 188 However, to date, there is no known gene that, when mutated, increases the likelihood of an autism diagnosis without also increasing the likelihood of intellectual disability or other 189 190 neurodevelopmental conditions (27). Consequently, genetic research is an important 191 biomedical tool in the study of autism and associated rare genetic conditions, with benefits 192 including personalised medicine, early identification of health risks, a better self-193 understanding, and a sense of community (28). To aid the development of evidence-based 194 care for autistic people and those with associated rare genetic conditions, it is crucial to better understand genetic differences between syndromic forms of autism and autism 195 196 without a known highly penetrant genetic influence. Further, by linking genetic mechanisms 197 to treatment outcomes, autistic people and those with associated rare genetic conditions can 198 be offered accurate information about what difficulties they may face both presently and in 199 the future, and what interventions may be effective for aspects of their lived experience that 200 they want or need support with.

201

202 EAGER (European Autism GEnomics Registry) is a European multicentre study that aims to 203 create a registry of 1,500 participants with a diagnosis of autism or a rare genetic condition 204 associated with autism. Participants will give a biosample and whole-genome sequencing 205 will be performed on extracted DNA; participants will also answer a series of questionnaires 206 related to autism, guality of life, mental and physical health, and research preferences. Using 207 extensive genetic and phenotypic data, EAGER will enable a better understanding of the 208 genetic architecture of autism and associated rare genetic conditions, as well as the 209 relationship between genetics and outcomes such as health, guality of life, and wellbeing.

210

The EAGER registry will allow participants to be recontacted for future research studies or
clinical trials that may be suitable for them. This will facilitate research by streamlining and

213 accelerating recruitment across Europe, as well as bring together key research and clinical 214 institutions, to the benefit of participants and their families. In line with tailoring evidence-215 based care to specific populations, clinical trials that are genetically-informed allow 216 researchers to invite participants who are the most suited to, and may benefit most from, a 217 treatment (29). Selective recruitment at the early stages of treatment development 218 encourages the downstream development of personalised medicine. 219 220 This project aims to be a catalyst for future research and clinical trials in autism and 221 associated rare genetic conditions in Europe. This will be achieved by connecting key sites 222 and allowing research groups and pharmaceutical companies planning research studies or 223 clinical trials to have access to a European registry of people who have consented to being 224 recontacted. EAGER data will also be shared via the Autism Sharing Initiative (ASI), a global 225 collaboration connecting autism data through federated mechanisms (30). The genetic, 226 phenotypic, and clinical data collected in EAGER can therefore be analysed with other 227 international autism datasets such as MSSNG (31), POND (32), LEAP (33), SPARK (34), 228 and Searchlight (35), providing the opportunity to investigate key research questions. 229 230 231 232 233 234 235 236

#### 2. METHODS AND ANALYSIS 237


238

#### 239 2.1. Study design and population

- 240 EAGER is an international, multisite registry of adults and children with a diagnosis of autism
- 241 or associated rare genetic conditions. Recruitment for EAGER will take place at 13 sites
- 242 across 8 European countries (see figure 1).

243


#### 244 Figure 1. EAGER collaborating centres



- 247 To be eligible, participants need to be over 2 years of age and have a diagnosed rare
- 248 genetic condition associated with autism and/or have a diagnosis of autism (see figure 2).
- 249 Decisions regarding which conditions and genetic variants to include have been made on the

250	basis of published literature (36) and discussions with experts in the field (TB, LG), with
251	consideration given to the penetrance, prevalence, and association with autism. For
252	participants with a diagnosis of autism only, and where existing genetic information is
253	available, recruitment will prioritise individuals within multiplex families and individuals with
254	genetic variants associated with autism (see figure 2). Participants will not be excluded from
255	the study based on any other characteristics such as co-occurring conditions, sex, or
256	intellectual disability.
257	
258	
259	
260	
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	
271	
272	

#### 273 Figure 2. EAGER protocol summary



# 275 2.2. Patient and public involvement and ethical consultations

276	Genetic research can involve complex ethical challenges, making it crucial to prioritise
277	ethical considerations and participatory research practices (21,28). Participatory research
278	practices can help ensure that the interests of our participants are appropriately represented
279	and that the study is beneficial to its participants and the wider community. EAGER was
280	developed with crucial input and feedback from community representatives via dedicated
281	working groups. Our autism working group consists of AIMS-2-TRIALS Autism
282	Representatives: autistic people and family members or carers of autistic people. Our rare
283	genetic conditions working group consists of parents/carers of people with rare genetic
284	conditions and/or representatives from European rare genetic conditions associations. As
285	EAGER was conceptualised and funded prior to the establishment of our lived experience
286	working groups, it is not a fully participatory research endeavour. This was discussed with
287	and understood by all members of the working groups at the outset of our collaboration.
288	Within these constraints, every effort was made to consult with our lived experience partners
289	throughout the lifespan of this project, and feedback was integrated to the greatest degree
290	possible.

291

The EAGER working groups have offered invaluable advice and feedback to guide the planning process of EAGER (see Box 1), either as part of working group meetings or through communication via email or contributions to collaborative documents. Open discussion within these groups was encouraged; as the groups included a variety of perspectives, there were naturally different solutions to questions. When no consensus was reached, the core research team made the final decision based on feasibility.

298

299

300

### 301 Box 1. Key examples of how patient and public involvement guided the EAGER study

- Refining the study rationale and clarifying perceived benefit of the study for autistic people
- Deciding on study name and logo
- Discussing ethical implications of the research, ensuring that appropriate safeguards are in place and that any limitations are transparently communicated to participants
- Ensuring that the information presented in study documents is clear, accessible, transparent, and sufficient to allow participants to make an informed decision about their participation
- Creating a "Data sharing Frequently Asked Questions" document to accompany the information sheet
- Developing different versions of information sheets tailored to the needs of our different participant groups (e.g., easy-read, adolescent information sheet)
- Ensuring that the consent forms are clear and transparent about what precisely a participant is consenting to
- Ensuring that the language used in study documents is appropriate and in line with community preferences
- Discussing the phenotypic measures used in the study and suggesting changes to the content/language of questionnaires
- Sharing all key study documents for feedback prior to submission for ethical approval
- Clearly stating that EAGER is against eugenics / prenatal testing for autism on participantfacing documents
- Detailing exactly what analyses will be performed on participant data and making it clear that no further analyses will occur without reconsenting
- Clarifying that analyses performed on EAGER data will need to be approved by a committee before they can begin
- Clarifying in the ethics documents that not all decisions were made based on consensus
- Adding a disclaimer in the protocol/ethics with regards to the fact that citing papers does not represent an endorsement of the language/aims of those papers or of the authors

Further, we conducted consultation with other stakeholders, ethical advisors, and additional working groups within the consortium, in order to evaluate risks and potentially sensitive implications of this research. We hope that the aforementioned groups will guide EAGER in the most beneficial direction for its participants and the wider community. These groups will continue to be consulted throughout the lifetime of the project.

308

309

310

#### 2.3. Participant recruitment, information sheets, and informed consent

311 Potential participants will be approached by representatives at each local site. Each site will

312 screen and recruit participants based upon recontact of participants from prior research

313 studies or prior/current patients that fit the inclusion criteria.

314

315 Written informed consent will be required for participation in the study and participants will be 316 provided with information sheets tailored to their age and levels of intellectual disability (see 317 figure 2 for details on documents for specific participant groups). A personal consultee will 318 be asked to consent on behalf of individuals who are deemed to not have capacity to 319 consent following a capacity to consent assessment. Due to the high prevalence of co-320 occurring intellectual disability in people with rare genetic conditions, these may make up a 321 significant proportion of the overall sample. Parental consent will be required for those under 322 the legal age of consent (e.g., 16 years old in the UK).

323

324 To take part in EAGER, participants must consent to core aspects of the study: giving a

325 blood or saliva sample (or permission to use a pre-existing sample), completing

326 questionnaires, being added to the registry, and data sharing.

327

#### 328 2.4. Biological sample collection

Participants will give a blood or saliva sample, depending on preference and
appropriateness. The Oragene®•DNA self-collection kits, as well as assisted collection kits
for those unable to collect their own sample, will be used for saliva collection. If existing
blood or saliva samples are available and have been stored appropriately, they can be used
in lieu of a new sample, with participant consent.

334

#### 335 **2.5.** Measures

Following collection of the biological sample, participants will be given access to an online

337 form with a series of questionnaires, focussing on autism, rare genetic conditions, co-

338 occurring physical and mental health conditions, opinions on research priorities, and quality

of life and wellbeing (see table 1). These will be a mixture of validated and non-validated

340 questionnaires that have been adapted for EAGER, and have been chosen to overlap with

other major initiatives or studies both within AIMS-2-TRIALS (37,38) and externally, such as

342 MSSNG (31), POND (32), LEAP (33), SPARK (34), and Simon's Searchlight (35). All

343 questionnaires have been translated into the local language of each site from English. The

online questionnaires will be completed by participants answering on behalf of themselves,

or by parents and consultees answering on behalf of the participant.

346

347

348

349

350

351

# 352 Table 1. EAGER questionnaires

Domain	Measure	Description	Respondents
Autism traits	Social Responsiveness Scale	65 items: Autism traits (including social	Adult self-report
	(SRS (39))	awareness, cognition, communication,	
		motivation, and repetitive interests and	
		behaviours)	
	Social Communication	40 items: Autism traits (including	Parent or consultee
	Questionnaire (SCQ, (40))	communication skills and social	report for child or
		functioning)	adult
Mental health	Strengths and Difficulties	25 items: General mental health across	Parent or consultee
	Questionnaire (SDQ, (41))	five scales (conduct problems,	report for adult or
		hyperactivity, emotional problems, peer	child
		problems, prosocial behaviour)	
	Patient Health Questionnaire-9	9 items: Core features of major	Adult self-report
	(PHQ-9, (42))	depressive disorder	
	Patient Health Questionnaire-A	9 items: Core features of major	Adolescent (16 and
	(PHQ-A, (43))	depressive disorder*	17 years) self-report
	Generalised Anxiety Disorder-	7 items: Core features of generalised	Adult self-report
	7 (GAD-7, (44))	anxiety disorder	
Quality of life	World Health Organization	26 items: Quality of life across four	Adult self-report
	Quality of Life-BREF (WHO-	domains (physical health, psychological	
	QOL-BREF, (45))	health, social relationships,	
		environment)	
	Cantrill Ladder (46)	1 item: Subjective quality of life (10 point	Adult self-report.
		scale from "worst possible life" to "best	Parent or consultee
		possible life")	report for child or
			adult.
Mental	Warwick-Edinburgh Mental	14 items: Mental wellbeing and health	Adult self-report.
wellbeing	Wellbeing Scales (WEMWBS,		Parent or consultee

	(47))		self-report <sup>+</sup>
Restrictive and repetitive	Adult Routines inventory (ARI, (48))	55 items: Restrictive and repetitive behaviours	Adult self-report
behaviours	Repetitive Behaviours Scale- Revised (RBS-R, (49))	43: Assessing restrictive and repetitive behaviours	Parent or consultee report for child or adult
ADHD	Conners' Adult ADHD Rating Scales (CAARS, (50))	26 items: Core features of ADHD	Adult self-report
	ADHD Rating Scale (51))	18 items: Core features of ADHD	Parent report for child Consultee report for adult <sup>^</sup>
Demographics	Non-validated questionnaire	16-25 items: Demographic characteristics	Adult self-report. Parent or consultee report for child or adult.
Co-occurring conditions	Non-validated questionnaire (adapted from Simons Searchlight (35))	Items assessing 168 diagnosed and self-diagnosed psychiatric, neurodevelopmental, and physical health conditions.	Adult self-report. Parent or consultee report for child or adult.
Medications	Non-validated questionnaire	1 item: Number of medications taken by participant per day	Adult self-report. Parent or consultee report for child or adult.
General	Non-validated questionnaire	7-11 items: Seizures, gross motor skills,	Adult self-report.
functioning	(adapted from (52))	language and communication, intellectual disability, support needs, sleep	Parent or consultee report for child or adult.
Voice of the	Non-validated questionnaire	7-13 items: Priorities for research	Adult self-report.

	Searchlight (35))		report for child or					
			adult.					
353	* Additional questions and assessment of suicidality in t	he original measure were removed for the pur	pose of this study and					
354	only the first core 9 items were included.							
355	^ The ADHD rating scale was adapted for use in EAGE	R to make it appropriate for adults and remove	e child-specific language.					
356	<sup>+</sup> Administered to parents and caregivers in relation to the	eir own mental wellbeing.						
357								
358								
359	2.6. Data analysis							
360	EAGER will collect genetic and phenotype	bic data, which can be analysed b	oth alone and in					
361	conjunction with other data collected with	nin AIMS-2-TRIALS and/or shared	d via the ASI.					
362	Research questions will be decided in co	llaboration with our community w	orking groups.					
363	Examples include identifying genetic var	iants that are associated with asp	ects of the core					
364	autism phenotype or conditions such as	epilepsy or major depressive disc	order, and					
365	identifying the association between gene	tic variants and/or polygenic scor	es and traits such					
366	as quality of life, levels of cognitive ability	y and executive function. The san	nple size of this					
367	study (n=1,500), which was driven by the	e available budget, is moderate-to	-large in the field					
368	and will be significantly enhanced via the	e planned data sharing and integr	ation.					
369								
370								
371								
372								
373								
374								
375								
376	3. DATA SHARING AND EAGER F	REGISTRY						

377

#### 378 3.1. Data sharing

- 379 Currently, funding bodies and participant groups have identified the need for research
- 380 groups to share their data to maximise the value of each research contribution, pool data to
- 381 address research questions that require a larger number of participants, or to carry out meta-
- analyses (53). For this reason, EAGER data will be shared via established AIMS-2-TRIALS
- 383 data sharing mechanisms as well as being directly implemented into the ASI as detailed
- 384 below. Rigorous safeguards will be implemented for access to data via established AIMS-2-
- 385 TRIALS mechanisms and via the ASI platform (30).

386

387 Researchers will not be able to access EAGER data without approval from a data access

committee, which will consist of autistic and non-autistic people, researchers, and members

389 of the rare genetic community.

390

#### 391 3.1.1. Autism Sharing Initiative (ASI)

392 The ASI is a new collaboration working to create the first federated, global network for

393 sharing genomic and clinical data in autism research. The ASI is led by software company

394 DNAStack and involves other collaborators such as Autism Speaks, Roche, and the Ontario

Brain Institute (please see (54) for the full list). This is an ongoing project and new

396 collaborators may be added.

397

398 Data sharing within the ASI will be built upon decentralised, federated data sharing

399 principles. Data federation allows researchers to search, access, and analyse data that

- 400 reside in different locations and are connected via a network, without the need for data to be
- 401 moved between institutions/researchers.

402

403	Data federation allows researchers to interrogate and analyse data hosted in different
404	locations, in compliance with data regulations and improving privacy and security. A
405	federated data network involves connecting individual datasets, which remain in their
406	protected local environments (i.e., at the research institution where the data was collected),
407	across one cloud-based network. To our knowledge, the ASI carries no additional risk to
408	participant re-identification than traditional data sharing. The ASI software is built upon
409	security standards developed by the Global Alliance for Genomics and Health (55), and
410	regularly updated in order to ensure that data are safeguarded.
411	
412	Within the ASI, data will include genomic, multi-omic, medical, and clinical data from
413	international autism research sources. With participant consent, EAGER data (genetic data,
414	data from online questionnaires, and existing data held at local sites) will be shared through
415	the ASI platform with any explicit identifiers removed.
416	
417	3.2. EAGER registry
418	The EAGER registry will allow participants to be contacted for future clinical trials and
419	research studies. Researchers viewing shared participant data will be able to contact the
420	coordinating site (King's College London) to request specific participant groups based upon
421	their desired criteria without access to participant personal information. King's College

- London will pass these requests onto the relevant local sites, who can send information
- 423 about the study or clinical trial to participants.

424

# 425 4. ETHICS AND DISSEMINATION

### 427 4.1. Ethics

428	EAGER has received ful	ethical approval from	ethics committees i	in the UK (REC
-----	------------------------	-----------------------	---------------------	----------------

429 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023) and Spain (HCB/2023/0038,

- 430 PIC-164-22). Approvals are in the process of being obtained from ethics committees in Italy,
- 431 Sweden, Ireland, and France. Please refer to the above section "Patient and Public
- 432 Involvement and Ethics Consultation" for detail on ethics and discussions within our
- 433 community working groups.

434

### 435 4.2. Dissemination

436 We plan to disseminate our findings widely via academic avenues, such as publications in

437 peer-reviewed major international scientific journals and conferences. In addition, we will

disseminate beyond academic avenues to ensure that our findings reach participants and

439 the wider communities, including the AIMS-2-TRIALS website (www.aims2trials.eu),

- 440 stakeholder meetings, and newsletters. As part of the overall AIMS-2-TRIALS project, we
- 441 have access to a European network including researchers, clinicians, and families within the
- 442 autism community. This network will also provide a forum for dissemination of research

443 findings and training opportunities.

444

445 Disclaimer: Citing papers does not represent an endorsement of the language used in these
446 papers, nor of the aims of the research or researchers.

447

448

449 **REFERENCES** 

- 450 1. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum
- 451 disorder. Nat Rev Dis Primers. 2020 Jan 16;6(1):1–23.
- 452 2. Kodak T, Bergmann S. Autism Spectrum Disorder: Characteristics, Associated
- 453 Behaviors, and Early Intervention. Pediatr Clin North Am. 2020 Jun;67(3):525–35.
- 454 3. Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global
- 455 prevalence of autism: A systematic review update. Autism Res. 2022 May;15(5):778–90.
- 456 4. Willsey HR, Willsey AJ, Wang B, State MW. Genomics, convergent neuroscience and
- 457 progress in understanding autism spectrum disorder. Nat Rev Neurosci. 2022
- 458 Jun;23(6):323–41.
- 459 5. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum
- disorder phenomenology in genetic disorders: a systematic review and meta-analysis.
- 461 The Lancet Psychiatry. 2015 Oct 1;2(10):909–16.
- 462 6. Lusk L, Vogel-Farley V, DiStefano C, Jeste S. Maternal 15q Duplication Syndrome. In:
- Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors.
- 464 GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited
- 465 2022 May 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK367946/
- 466 7. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-
- 467 occurring mental health diagnoses in the autism population: a systematic review and
   468 meta-analysis. Lancet Psychiatry. 2019 Oct;6(10):819–29.
- 469 8. Tye C, Runicles AK, Whitehouse AJO, Alvares GA. Characterizing the Interplay
- 470 Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative
- 471 Review. Front Psychiatry. 2018;9:751.

472	9.	van Heijst BF	Deserno MK.	Rhebergen D	, Geurts HM.	Autism and	depression a

- 473 connected: A report of two complimentary network studies. Autism. 2020 Apr;24(3):680–
  474 92.
- 475 10. Hollocks MJ, Lerh JW, Magiati I, Meiser-Stedman R, Brugha TS. Anxiety and depression
- in adults with autism spectrum disorder: a systematic review and meta-analysis.
- 477 Psychological Medicine. 2019 Mar;49(4):559–72.
- 478 11. Wang J, Ma B, Wang J, Zhang Z, Chen O. Global prevalence of autism spectrum
- disorder and its gastrointestinal symptoms: A systematic review and meta-analysis.
- 480 Front Psychiatry. 2022 Aug 23;13:963102.
- 481 12. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges.
- 482 Neuropsychiatr Dis Treat. 2017 Dec 18;14:1–10.
- 483 13. Acampa M, Guideri F. Cardiac disease and Rett syndrome. Arch Dis Child. 2006
  484 May;91(5):440–3.
- 485 14. Katz DM, Dutschmann M, Ramirez JM, Hilaire G. Breathing Disorders in Rett Syndrome:

486 Progressive Neurochemical Dysfunction in the Respiratory Network after Birth. Respir

487 Physiol Neurobiol. 2009 Aug 31;168(1–2):101–8.

- 488 15. Driscoll DJ, Miller JL, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Mirzaa GM,
- 489 Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. GeneReviews® [Internet].
- 490 Seattle (WA): University of Washington, Seattle; 1993 [cited 2023 Sep 18]. Available
- 491 from: http://www.ncbi.nlm.nih.gov/books/NBK1330/
- 492 16. Islam MP. Tuberous Sclerosis Complex. Semin Pediatr Neurol. 2021 Apr;37:100875.
- 493 17. Schaaf RC, Toth-Cohen S, Johnson SL, Outten G, Benevides TW. The everyday
- 494 routines of families of children with autism: examining the impact of sensory processing
- difficulties on the family. Autism. 2011 May;15(3):373–89.

496	18. Green D, Chandler S, Charman T, Simonoff E, Baird G. Brief Report: DSM-5 Sensory
497	Behaviours in Children With and Without an Autism Spectrum Disorder. J Autism Dev
498	Disord. 2016 Nov 1;46(11):3597–606.
499	19. Lai MC, Anagnostou E, Wiznitzer M, Allison C, Baron-Cohen S. Evidence-based support
500	for autistic people across the lifespan: maximising potential, minimising barriers, and
501	optimising the person-environment fit. Lancet Neurol. 2020 May;19(5):434–51.
502	20. Lord C, Charman T, Havdahl A, Carbone P, Anagnostou E, Boyd B, et al. The Lancet
503	Commission on the future of care and clinical research in autism. The Lancet. 2022
504	Jan;399(10321):271–334.
505	21. Heraty S, Lautarescu A, Belton D, Boyle A, Cirrincione P, Doherty M, et al. Bridge-
506	building between communities: Imagining the future of biomedical autism research. Cell.
507	2023 Aug 31;186(18):3747–52.
508	22. Sandbank M, Bottema-Beutel K, Crowley S, Cassidy M, Dunham K, Feldman JI, et al.
509	Project AIM: Autism intervention meta-analysis for studies of young children.
510	Psychological Bulletin. 2020;146(1):1–29.
511	23. Braga LAM, Conte Filho CG, Mota FB. Future of genetic therapies for rare genetic
512	diseases: what to expect for the next 15 years? Ther Adv Rare Dis. 2022 Jun
513	10;3:26330040221100840.

514 24. Feroe AG, Uppal N, Gutiérrez-Sacristán A, Mousavi S, Greenspun P, Surati R, et al.
515 Medication Use in the Management of Comorbidities Among Individuals With Autism
516 Spectrum Disorder From a Large Nationwide Insurance Database. JAMA Pediatrics.
517 2021 Sep 1;175(9):957–65.

- 518 25. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of
- 519 Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA
- 520 Psychiatry. 2019 Oct 1;76(10):1035–43.
- 521 26. Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F. Heritability of autism spectrum disorders:
- 522 a meta-analysis of twin studies. Journal of Child Psychology and Psychiatry.
- 523 2016;57(5):585–95.
- 524 27. Myers SM, Challman TD, Bernier R, Bourgeron T, Chung WK, Constantino JN, et al.
- 525 Insufficient Evidence for "Autism-Specific" Genes. Am J Hum Genet. 2020 May
- 526 7;106(5):587–95.
- 527 28. Natri HM, Chapman CR, Heraty S, Dwyer P, Walker N, Kapp SK, et al. Ethical
- challenges in autism genomics: Recommendations for researchers. European Journal of
   Medical Genetics. 2023 Sep 1;66(9):104810.
- 530 29. Díaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marín O, Bagni C, et al. A
- 531 white paper on a neurodevelopmental framework for drug discovery in autism and other
- neurodevelopmental disorders. Eur Neuropsychopharmacol. 2021 Jul;48:49–88.
- 30. DNAstack [Internet]. [cited 2023 Oct 8]. DNAstack launches Neuroscience AI to
- 534 accelerate collaborative research and discovery, DNAstack. Available from:
- 535 https://dnastack.com/news-neuroscience-ai-launch-announcement/
- 536 31. MSSNG [Internet]. [cited 2023 Sep 18]. Available from: https://research.mss.ng/
- 537 32. POND. Your Research Priorities [Internet]. Province of Ontario Neurodevelopmental
- Network. [cited 2023 Apr 11]. Available from: https://pond-network.ca/your-researchpriorities/

540 33. Charman T, Loth E, Tillmann J, Crawley D, Wooldridge C, Goyard D, et al. T	I. The EU-
--	------------

- 541 AIMS Longitudinal European Autism Project (LEAP): clinical characterisation. Molecular
- 542 Autism. 2017 Jun 23;8(1):27.
- 543 34. SPARK [Internet]. [cited 2023 Sep 18]. Available from: https://sparkforautism.org/
- 35. SFARI [Internet]. 2019 [cited 2023 Sep 18]. SFARI | Simons Searchlight. Available from:
- 545 https://www.sfari.org/resource/simons-searchlight/
- 36. Rolland T, Cliquet F, Anney RJL, Moreau C, Traut N, Mathieu A, et al. Phenotypic
- 547 effects of genetic variants associated with autism. Nat Med. 2023 Jul;29(7):1671–80.
- 548 37. AIMS-2-TRIALS Autism Research For Europe [Internet]. 2018 [cited 2023 Oct 8].
- 549 Available from: https://www.aims-2-trials.eu/
- 38. Oakley BFM, Loth E, Jones EJH, Chatham CH, Murphy DG. Advances in the

identification and validation of autism biomarkers. Nat Rev Drug Discov. 2022

552 Oct;21(10):697–8.

- 39. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al.
- 554 Validation of a Brief Quantitative Measure of Autistic Traits: Comparison of the Social
- Responsiveness Scale with the Autism Diagnostic Interview-Revised. J Autism Dev
  Disord. 2003 Aug 1;33(4):427–33.

40. (SCQ) Social Communication Questionnaire [Internet]. [cited 2023 Sep 18]. Available

- 558 from: https://www.wpspublish.com/scq-social-communication-questionnaire.html
- 41. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child
  Psychol Psychiatry. 1997 Jul;38(5):581–6.
- 42. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
   measure. J Gen Intern Med. 2001 Sep;16(9):606–13.

563	43. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for
564	adolescents: validation of an instrument for the assessment of mental disorders among
565	adolescent primary care patients. J Adolesc Health. 2002 Mar;30(3):196–204.
566	44. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing
567	Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine. 2006 May
568	22;166(10):1092–7.
569	45. WHOQOL - Measuring Quality of Life  The World Health Organization [Internet]. [cited
570	2023 Sep 18]. Available from: https://www.who.int/tools/whoqol
571	46. Cantril H. The pattern of human concerns. New Brunswick, N.J.: Rutgers University
572	Press; 1966. 427 p.
573	47. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-
574	Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health
575	and Quality of Life Outcomes. 2007 Nov 27;5(1):63.
576	48. Evans DW, Uljarević M, Lusk LG, Loth E, Frazier T. Development of Two Dimensional
577	Measures of Restricted and Repetitive Behavior in Parents and Children. Journal of the
578	American Academy of Child & Adolescent Psychiatry. 2017 Jan 1;56(1):51–8.
579	49. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Repetitive Behavior Scale-Revised
580	[Internet]. 2014 [cited 2023 Sep 18]. Available from:
581	http://doi.apa.org/getdoi.cfm?doi=10.1037/t17338-000
582	50. Macey KD. Conners' Adult ADHD Rating Scales (CAARS). Archives of Clinical
583	Neuropsychology. 2003 May 1;18(4):431–7.
584	51. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale—IV: Checklists,
585	norms, and clinical interpretation. New York, NY, US: The Guilford Press; 1998. viii, 79

587	52. Keute M, Mi	ller MT, Krishnar	n ML, Sadhwani A,	Chamberlain S,	Thibert RL, et al.
-----	-----------------	-------------------	-------------------	----------------	--------------------

- 588 Angelman syndrome genotypes manifest varying degrees of clinical severity and
- developmental impairment. Mol Psychiatry. 2021 Jul;26(7):3625–33.
- 53. Lombardo MV, Lai MC, Baron-Cohen S. Big data approaches to decomposing
- 591 heterogeneity across the autism spectrum. Mol Psychiatry. 2019 Oct;24(10):1435–50.
- 592 54. Digital Supercluster [Internet]. [cited 2023 Oct 8]. Autism Sharing Initiative. Available
- 593 from: https://www.digitalsupercluster.ca/projects/autism-sharing-initiative/
- 55. Global Alliance for Genomics and Health. Enabling responsible genomic data sharing for
- the benefit of human health [Internet]. 2023 [cited 2023 Apr 11]. Available from:
- 596 https://www.ga4gh.org/

597

598

#### 599 **AUTHOR CONTRIBUTIONS:**

- 600 Conceptualisation: MB, AL, SH, SD, PV, RP, AG, KVdB, EE, CO, VR, JT, BO, DM, LG,
- TB, CC, TC. Funding acquisition: DM, CC, TC. Project administration: MB, AL, DM, LG,
- TB, CC. TC. Supervision: AL, TC. Visualisation: MB, AL. Data collection: MB, AL, MA,
- RB, ABH, NB, SB, PB, JB, SC, RCE, MCB, JCF, PC, AD, RD, ME, MH, NM, GM, RM, CJM,
- SM, VM, APR, CPS, MS, KT, CT, FV, GO, BM, LG, TC. Writing original draft: MB, AL,
- 605 TC. Writing review and editing: All authors

606

### 607 FUNDING STATEMENT:

608 This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking

- under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking
- receives support from the European Union's Horizon 2020 research and innovation

611 programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI and from Horizon Europe 612 [grant agreement no. 101057385] and from Horizon Europe [grant agreement no. 613 101057385] and from UK Research and Innovation (UKRI) under the UK government's 614 Horizon Europe funding guarantee [grant no.10039383] (R2D2-MH). The funders had no 615 role in the design of the study; in the collection, analyses, or interpretation of data; in the 616 writing of the manuscript, or in the decision to publish the results. Any views expressed are 617 those of the author(s) and not necessarily those of the funders. In addition, SB receives 618 funding from Swedish Research Council and Region Stockholm. CT receives funding from 619 Epilepsy Research UK, Autistica, the Baily Thomas Charitable Fund and the Tuberous 620 Sclerosis Association. LG receives funding from Horizon Europe: Risk and Resilience in 621 Developmental Diversity and Mental Health (R2D2-MH). CPS receives funding from 622 Foundation of Prader-Willi Research, European Joint Program for Rare Diseases, Illumina, 623 German Children's Cancer Foundation, and the German Ministry of Education and 624 Research. RB, RM, SC, BM receive funding from the Italian Ministry of Health (Ricerca 625 Corrente and 5x1000 to IRCCS Fondazione Stella Maris). Genomic data utilised here will be 626 sequenced in part/whole through the financial contribution of F Hoffmann La-Roche. This 627 paper represents independent research part-funded by the NIHR Maudsley Biomedical 628 Research Centre at South London and Maudsley NHS Foundation Trust and King's College 629 London. The views expressed are those of the author(s) and not necessarily those of the 630 NIHR or the Department of Health and Social Care.

631

#### 632 **COMPETING INTEREST STATEMENT:**

In the past 3 years TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and
Servier and has received royalties from Sage Publications and Guilford Publications. DM has
received funding for a PhD studentship from Compass, and for consulting from Jaguar
Therapeutics and Hoffman Le Roche. GM receives funding for an investigator-initiated study
from Compass Pathways; no financial or other conflict of interest with the present study. SB

discloses that he has in the last 3 years acted as an author, consultant, or lecturer for

- 639 Medice, Roche, and Linus Biotechnology. SB receives royalties for textbooks and diagnostic
- tools from Hogrefe, UTB, Ernst Reinhardt, Kohlhammer, and Liber, and is a partner at
- 641 NeuroSupportSolutions International AB. CC is a full-time employee of Genentech and owns
- 642 stocks or RSUs in Roche Holdings, Ltd. MA is the UK chief investigator for a trial sponsored
- by Roche (a phase II, randomised, double-blind, placebo-controlled, parallel group study to
- 644 evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of treatment with
- basmasanil in participants aged 2 to 14 years old with dup15q syndrome followed by a 2-
- 646 year optional open-label extension). LB served on an advisory board to Kingdom
- 647 therapeutics in 2022.

648

#### 649 WORD COUNT: 2418